Bleeding risk ends aspirin-clopidogrel trial

10/10/2011 | TheHeart.org (Montreal) (free registration)

The National Institute of Neurological Disorders and Stroke has halted the study of an aspirin-clopidogrel combination in the Secondary Prevention of Small Subcortical Strokes trial. Mortality rates and bleeding risk were higher for that combination, and an analysis showed little chance of benefit.

View Full Article in:

TheHeart.org (Montreal) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX